Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Long-term immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population Secondary Study Based on a Randomized Clinical Trial

Tian Yao, Xiaohong Zhang, Shengcai Mu, Yana Guo, Xiuyang Xu, Junfeng Huo, Zhiyun Wei, Ling Liu, Xiaoqing Li, Hong Li, Rongqin Xing, Yongliang Feng, Jing Chen, Lizhong Feng, Suping Wang
doi: https://doi.org/10.1101/2022.06.22.22276690
Tian Yao
1First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, China
3Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaohong Zhang
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shengcai Mu
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yana Guo
2School of Public Health, Shanxi Medical University, Taiyuan, China
3Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China
BM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiuyang Xu
2School of Public Health, Shanxi Medical University, Taiyuan, China
3Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China
BM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junfeng Huo
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiyun Wei
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling Liu
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoqing Li
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Li
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rongqin Xing
6Outpatient Department of Shanxi Aviation Industry Group Co. LTD
BM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongliang Feng
2School of Public Health, Shanxi Medical University, Taiyuan, China
3Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: supingwang{at}sxmu.edu.cn 1508717672{at}qq.com 524210737{at}qq.com yongliang.feng{at}sxmu.edu.cn
Jing Chen
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: supingwang{at}sxmu.edu.cn 1508717672{at}qq.com 524210737{at}qq.com yongliang.feng{at}sxmu.edu.cn
Lizhong Feng
4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
5Shanxi Provincial Key Laboratory for major infectious disease response
MM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: supingwang{at}sxmu.edu.cn 1508717672{at}qq.com 524210737{at}qq.com yongliang.feng{at}sxmu.edu.cn
Suping Wang
2School of Public Health, Shanxi Medical University, Taiyuan, China
3Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: supingwang{at}sxmu.edu.cn 1508717672{at}qq.com 524210737{at}qq.com yongliang.feng{at}sxmu.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background BBIBP-CorV vaccine with two doses and an interval of 3-4 weeks had been proved to have good immunogenicity and efficacy as well as an acceptable safety profile according to our initial research and other similar studies. Maintaining adequate neutralizing antibody levels is also necessary for long-term protection, especially in the midst of the COVID-19 pandemic. Our aim was to evaluate the immune persistence of neutralizing antibody elicited by BBIBP-CorV vaccines with day 0-14, 0-21 and 0-28 schedule, and assess the immunogenicity and safety of a homologous booster dose in the high-risk occupational population aged 18-59 years.

Methods A total of 809 eligible participants, aged 18-59 years, were recruited and randomly allocated to receive BBIBP-CorV vaccine with day 0-14, 0-21 or 0-28 schedule respectively between January and May 2021 in Taiyuan City, Shanxi Province, China among the public security officers and the airport ground staff in initial study. In this secondary study, the responders (GMT ≥ 16) at day 28 after priming two-dose vaccine were followed up at months 3, 6 and 10 to evaluate the immune persistence of three two-dose schedules. At month 10, eligible participants of three two-dose schedules were received a homologous booster dose respectively (hereafter abbreviated as 0-14d-10m group, 0-21d-10m group and 0-28d-10m group), and followed up at day 28 post-booster to assess the safety and immunogenicity of the booster dose. The contents of follow-up included the blood samples, oropharyngeal/nasal swabs, and adverse reactions collection. The main outcomes of the study included geometric mean titers (GMT) of neutralizing antibody to live SARS-CoV-2, the positive rates of different criteria and the constituent ratio of GMT of neutralizing antibodies at different follow-up point. Meanwhile, we explored the kinetics of antibody levels of different vaccination regimens by generalized estimating equations (GEE) and used exponent curve model to predict the duration of maintaining protected antibody after the booster dose. We also determined predictors of maintaining protected antibody level within 10 months after the second dose by Cox proportional hazards regression model and nomogram. The trial was registered with ChiCTR.org.cn (ChiCTR2100041705, ChiCTR2100041706).

Results The number of 241, 247 and 256 responders (GMT ≥ 16) at day 28 after two-dose BBIBP-CorV vaccine in 0-14d, 0-21d and 0-28d schedule were followed-up at months 3, 6, and 10 for immune persistence evaluation. At month 10, a total of 390 participants were eligible and received a booster dose with 130 participants in the 0-14d-10m, 0-21d-10m and 0-28d-10m group respectively, of whom 74.1% (289/390) were male, with a mean age of 37.1±10.3 years. The GMT of neutralizing antibody in 0-28d-10m and 0-21d-10m group were significantly higher than 0-14d-10m group at month 3 (GMT: 71.6 & 64.2 vs 46.4, P<0.0001), month 6 (GMT: 47.1 & 42.8 vs 30.5, P < 0.0001) and month 10 (GMT: 32.4 vs 20.3, P < 0.0001; 28.8 vs 20.3, P=0.0004) after the second dose. A sharply decrease by 4.85-fold (GMT: 94.4-20.3), 4.67-fold (GMT: 134.4-28.8) and 4.49-fold (GMT: 145.5-32.4) was observed from day 28 to month 10 after the second dose in 0-14d-10m, 0-21d-10m and 0-28d-10m group, respectively, and they had similar decline kinetics (P=0.67). At 28 days after booster dose, a remarkable rebound in neutralizing antibody (GMT: 246.2, 277.5 and 288.6) were observed in three groups, respectively. Notably, the GMT after booster dose was not affected by priming two-dose schedule. The predictive duration of neutralizing antibody declining to the cutoff level of positive antibody response may be 18.08 months, 18.83 months and 19.08 months after booster dose in three groups, respectively. Long-term immune persistence within 10 months after the second dose was associated with age<40, female, and history of influenza vaccination. All adverse reactions were mild after the booster injection. None of the participants were infected SARS-CoV-2 during the trial period.

Conclusions The priming two-dose BBIBP-CorV vaccine with 0-28 days and 0-21 days schedule could lead a longer persistence of neutralizing antibody than 0-14 days schedule. Maintaining long-term immune persistence was also associated with age<40, female, and history of influenza vaccination. Regardless of priming two-doses vaccination regimens, a homologous booster dose led to a strong rebound in neutralizing antibody and might elicit satisfactory persistent immunity.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2100041705,ChiCTR2100041706

Funding Statement

The study was supported by the COVID-19 Project of Shanxi Provincial Finance, the Project of Shanxi Provincial Key Laboratory for major infectious disease response, and the COVID-19 Scientific Research Project of Health Commission of Shanxi Provincial.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Ethics Committee of Shanxi Provincial Center for Disease Control (SXCDCIRBPJ2020056001) and Prevention

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† Joint supervisors

Data Availability

In this study, the full protocol and the datasets are available, following manuscript publication, upon request from the corresponding author (Professor Suping Wang, supingwang{at}sxmu.edu.cn), following the provision of ethics approval.

  • Abbreviations

    SARS-CoV-2
    Severe acute respiratory syndrome coronavirus 2;
    COVID-19
    Coronavirus disease 2019;
    GMT
    Geometric mean titer;
    CI
    Confdence interval; BMI: Body mass index;
    RT-PCR
    Reverse transcriptase-polymerase chain reaction;
    WHO
    World Health Organization.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted June 26, 2022.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Long-term immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population Secondary Study Based on a Randomized Clinical Trial
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Long-term immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population Secondary Study Based on a Randomized Clinical Trial
    Tian Yao, Xiaohong Zhang, Shengcai Mu, Yana Guo, Xiuyang Xu, Junfeng Huo, Zhiyun Wei, Ling Liu, Xiaoqing Li, Hong Li, Rongqin Xing, Yongliang Feng, Jing Chen, Lizhong Feng, Suping Wang
    medRxiv 2022.06.22.22276690; doi: https://doi.org/10.1101/2022.06.22.22276690
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Long-term immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population Secondary Study Based on a Randomized Clinical Trial
    Tian Yao, Xiaohong Zhang, Shengcai Mu, Yana Guo, Xiuyang Xu, Junfeng Huo, Zhiyun Wei, Ling Liu, Xiaoqing Li, Hong Li, Rongqin Xing, Yongliang Feng, Jing Chen, Lizhong Feng, Suping Wang
    medRxiv 2022.06.22.22276690; doi: https://doi.org/10.1101/2022.06.22.22276690

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Epidemiology
    Subject Areas
    All Articles
    • Addiction Medicine (430)
    • Allergy and Immunology (756)
    • Anesthesia (221)
    • Cardiovascular Medicine (3294)
    • Dentistry and Oral Medicine (364)
    • Dermatology (279)
    • Emergency Medicine (479)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
    • Epidemiology (13376)
    • Forensic Medicine (19)
    • Gastroenterology (899)
    • Genetic and Genomic Medicine (5153)
    • Geriatric Medicine (482)
    • Health Economics (783)
    • Health Informatics (3268)
    • Health Policy (1140)
    • Health Systems and Quality Improvement (1190)
    • Hematology (431)
    • HIV/AIDS (1017)
    • Infectious Diseases (except HIV/AIDS) (14629)
    • Intensive Care and Critical Care Medicine (913)
    • Medical Education (477)
    • Medical Ethics (127)
    • Nephrology (523)
    • Neurology (4925)
    • Nursing (262)
    • Nutrition (730)
    • Obstetrics and Gynecology (883)
    • Occupational and Environmental Health (795)
    • Oncology (2524)
    • Ophthalmology (724)
    • Orthopedics (281)
    • Otolaryngology (347)
    • Pain Medicine (323)
    • Palliative Medicine (90)
    • Pathology (543)
    • Pediatrics (1302)
    • Pharmacology and Therapeutics (550)
    • Primary Care Research (557)
    • Psychiatry and Clinical Psychology (4212)
    • Public and Global Health (7504)
    • Radiology and Imaging (1706)
    • Rehabilitation Medicine and Physical Therapy (1013)
    • Respiratory Medicine (980)
    • Rheumatology (480)
    • Sexual and Reproductive Health (497)
    • Sports Medicine (424)
    • Surgery (548)
    • Toxicology (72)
    • Transplantation (236)
    • Urology (205)